{"id":993434,"date":"2026-08-11T10:36:02","date_gmt":"2026-08-11T14:36:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\/"},"modified":"2026-08-11T10:36:02","modified_gmt":"2026-08-11T14:36:02","slug":"intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\/","title":{"rendered":"Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System"},"content":{"rendered":"

\nAll clinical data collection across the Company’s FDA 510(k) clinical study program is complete; FDA submission on track for second half of 2026
\n<\/h2>\n
\n

NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the completion of its multi-site Method Comparison Study for the Intelligent Fingerprinting Drug Screening System, one of several studies underpinning the Company’s FDA 510(k) submission for U.S. market clearance for detection of the opiate codeine. All clinical data collection across the Company’s FDA 510(k) clinical study program is now complete.<\/p>\n

Following ICH GCP (International Council for Harmonisation Good Clinical Practice) guidelines, the study was conducted across three independent U.S. clinical sites over three weeks in partnership with CenExel Clinical Research, Inc. A total of 135 participants were enrolled, with the study population structured to represent the demographic diversity of the U.S. population. The screening process was administered by nine operator participants representing typical workplace drug screening personnel. Data analysis is currently underway, with all specimens to be independently verified via liquid chromatography-tandem mass spectrometry (\u201cLC-MS\/MS\u201d) analysis.<\/p>\n

The Method Comparison Study was designed to show that typical users in occupational health, HR, and workplace safety can operate the Intelligent Fingerprinting Drug Screening System accurately and effectively in the field. The study evaluated this by measuring sensitivity, specificity, and accuracy in pre-employment and workplace screening environments, making it one of the most operationally relevant components of the Company’s FDA 510(k) submission.<\/p>\n

\n “Completing this final study on schedule is the milestone the entire program has been building toward. It amounts to a substantial body of work and clinical evidence,”\u00a0said Harry Simeonidis, President and CEO at Intelligent Bio Solutions.\u00a0“We are now firmly in the final stretch of data analysis and assembly of our FDA 510(k) submission package, and we remain focused on bringing our technology to the U.S. market.”<\/em>\n <\/p>\n

The completion of data collection in this final study concludes a structured, multi-study clinical program designed to address safety, accuracy, usability, specificity, and precision requirements. The Company now moves into analysis, compilation, and finalization of its 510(k) submission package, targeting submission in the second half of 2026, ahead of planned entry into the multi-billion-dollar U.S. market.<\/p>\n

\n About Intelligent Bio Solutions Inc.<\/strong>
\n \u202f<\/strong>\n <\/p>\n

Intelligent Bio Solutions Inc. (Nasdaq: INBS) is a medical technology\u00a0company delivering\u00a0intelligent, rapid, non-invasive testing solutions. The Company believes that its\u00a0Intelligent Fingerprinting Drug Screening System\u00a0will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in\u00a0additional\u00a0fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company\u2019s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and\u00a0logistics\u00a0firms, mining, drug treatment organizations, and coroners.<\/p>\n

For more information, visit:\u202fhttps:\/\/ibs.inc\/\u202f<\/a><\/p>\n

\n Forward-Looking Statements\u00a0<\/strong>\n <\/p>\n

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.\u2019s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, secure regulatory clearance or approvals,\u00a0and timelines to enter the U.S. market,\u00a0among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date\u00a0made,\u00a0actual results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including \u201cbelieves,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cintends,\u201d \u201cpotential,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d and \u201capproximately,\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions\u2019 public filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.\u00a0<\/p>\n

\n Company Contact<\/strong>\u00a0
Intelligent Bio Solutions Inc.\u202f\u00a0\u00a0
info@ibs.inc<\/a><\/p>\n

\n Investor & Media Contact<\/strong>\u00a0\u00a0
Valter Pinto, Managing Director\u202f\u00a0\u00a0
KCSA Strategic Communications\u202f\u00a0\u00a0
PH: (212) 896-1254\u202f\u00a0\u00a0
INBS@kcsa.com<\/a>\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

All clinical data collection across the Company’s FDA 510(k) clinical study program is complete; FDA submission on track for second half of 2026 NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the completion of its multi-site Method Comparison Study for the Intelligent Fingerprinting Drug Screening System, one of several studies underpinning the Company’s FDA 510(k) submission for U.S. market clearance for detection of the opiate codeine. All clinical data collection across the Company’s FDA 510(k) clinical study program is now complete. Following ICH GCP (International Council for Harmonisation Good Clinical Practice) guidelines, the study was conducted across three … <\/p>\n

Continue reading “Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-993434","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nIntelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"All clinical data collection across the Company’s FDA 510(k) clinical study program is complete; FDA submission on track for second half of 2026 NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the completion of its multi-site Method Comparison Study for the Intelligent Fingerprinting Drug Screening System, one of several studies underpinning the Company’s FDA 510(k) submission for U.S. market clearance for detection of the opiate codeine. All clinical data collection across the Company’s FDA 510(k) clinical study program is now complete. Following ICH GCP (International Council for Harmonisation Good Clinical Practice) guidelines, the study was conducted across three … Continue reading "Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-11T14:36:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNjkwMyM3NzY3MTA3IzIxODk1NjU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System\",\"datePublished\":\"2026-08-11T14:36:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\\\/\"},\"wordCount\":802,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNjkwMyM3NzY3MTA3IzIxODk1NjU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\\\/\",\"name\":\"Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNjkwMyM3NzY3MTA3IzIxODk1NjU=\",\"datePublished\":\"2026-08-11T14:36:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNjkwMyM3NzY3MTA3IzIxODk1NjU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNjkwMyM3NzY3MTA3IzIxODk1NjU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\/","og_locale":"en_US","og_type":"article","og_title":"Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System - Market Newsdesk","og_description":"All clinical data collection across the Company’s FDA 510(k) clinical study program is complete; FDA submission on track for second half of 2026 NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the completion of its multi-site Method Comparison Study for the Intelligent Fingerprinting Drug Screening System, one of several studies underpinning the Company’s FDA 510(k) submission for U.S. market clearance for detection of the opiate codeine. All clinical data collection across the Company’s FDA 510(k) clinical study program is now complete. Following ICH GCP (International Council for Harmonisation Good Clinical Practice) guidelines, the study was conducted across three … Continue reading \"Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-11T14:36:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNjkwMyM3NzY3MTA3IzIxODk1NjU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System","datePublished":"2026-08-11T14:36:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\/"},"wordCount":802,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNjkwMyM3NzY3MTA3IzIxODk1NjU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\/","name":"Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNjkwMyM3NzY3MTA3IzIxODk1NjU=","datePublished":"2026-08-11T14:36:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNjkwMyM3NzY3MTA3IzIxODk1NjU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNjkwMyM3NzY3MTA3IzIxODk1NjU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-announces-completion-of-method-comparison-study-for-the-intelligent-fingerprinting-drug-screening-system\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/993434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=993434"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/993434\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=993434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=993434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=993434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}